Physician profile
Lionel Ramirez
NPI 1508387200
$2,032.87
in general payments reported to CMS, 2019-2025
19 companies · $683 in 2025
The $683 reported for 2025 was more than what 88% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $231 · 2022: $432 · 2023: $220 · 2024: $467 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,370.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $416.56 | 2023-2025 | Airsupra, Farxiga |
| Amgen INC. | $193.12 | 2021-2025 | Repatha, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $184.68 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.74 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $151.79 | 2022-2025 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $148.26 | 2022 | |
| Lilly USA, LLC | $146.43 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $117.28 | 2022-2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.04 | 2023-2025 | Xifaxan, Relistor |
| Dexcom, INC. | $89.97 | 2021-2024 | Dexcom G6 Transmitter |
| Organon LLC | $56.08 | 2025 | |
| Pfizer INC. | $51.41 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $45.77 | 2024 | Voquezna |
| Abbvie INC. | $42.66 | 2022-2024 | |
| Shield Therapeutics INC | $31.67 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $29.96 | 2022 | |
| Ge Healthcare | $24.42 | 2022 | |
| Xeris Pharmaceuticals, INC. | $21.10 | 2021 | |
| Inspire Medical Systems, INC. | $20.93 | 2023 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lionel Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.